Literature DB >> 7877114

The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders.

I Heuser1, A Yassouridis, F Holsboer.   

Abstract

This report summarizes our extensive experience with the application of the DEX/CRH test to assess hypothalamic-pituitary-adrenal-system (HPA) alteration in patients with psychiatric disorders. The application of this combined dexamethasone suppression/CRH-challenge (DEX/CRH) test requires individuals to take 1.5 mg dexamethasone (DEX) at 23:00 h orally the previous night. On the day of the test, 100 micrograms human CRH are administered to the subjects under study at 15:00 h intravenously as a bolus, and blood samples for the determination of plasma cortisol and ACTH are drawn every 15 min from 14:00 h to 18:00 h. DEX/CRH-test results from 96 patients with major depression (MDE), 11 with a manic episode (MA), 9 with panic disorder (PD), 24 with a schizophrenic psychosis (SP), and 82 healthy control subjects served as the data base for this report. Three major conclusions can be drawn from statistical analysis of these data: 1. Psychiatric patients (n = 140), regardless of diagnostic classification, release significantly more cortisol and ACTH after DEX and additional CRH in comparison with age-matched controls. This hormonal release pattern (DEX CRH-test phenomenon) supports the assumption that psychiatric patients are prone to an altered glucocorticoid feedback regulation during the acute illness episode. This supports the notion that the DEX/CRH-test phenomenon constitutes a neuroendocrine sign of these various disorders and emphasizes the usefulness of the DEX/CRH test as a laboratory test to monitor the course of these disorders. 2. The sensitivity of the DEX/CRH test for MDE (about 80%) greatly exceeds that of the standard DST (1-2 mg of DEX), which has been reported to average about 44% in a meta-analysis of the literature data; in our sample the sensitivity of the DST was about 25%. 3. The sensitivity of the DEX/CRH test can be further increased to above 90% if subjects are clustered into four different age ranges: age < 35 years, age between 35 and 50 years, age between 50 and 70 years, and age above 70 years. 4. By reducing the time points of blood sampling for ACTH and cortisol to as few as five (15:00, 15:30, 15:45, 16:00, and 16:15 h), the DEX/CRH-test procedure becomes more convenient and more easily applicable without reducing its sensitivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7877114     DOI: 10.1016/0022-3956(94)90017-5

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  124 in total

1.  Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.

Authors:  John C Umhau; Reza Momenan; Melanie L Schwandt; Erick Singley; Mariel Lifshitz; Linda Doty; Lauren J Adams; Valentina Vengeliene; Rainer Spanagel; Yan Zhang; Jun Shen; David T George; Daniel Hommer; Markus Heilig
Journal:  Arch Gen Psychiatry       Date:  2010-10

2.  Associations among parenting experiences during childhood and adolescence, hypothalamus-pituitary-adrenal axis hypoactivity, and hippocampal gray matter volume reduction in young adults.

Authors:  Kosuke Narita; Kazuyuki Fujihara; Yuichi Takei; Masashi Suda; Yoshiyuki Aoyama; Toru Uehara; Takehiko Majima; Hirotaka Kosaka; Makoto Amanuma; Masato Fukuda; Masahiko Mikuni
Journal:  Hum Brain Mapp       Date:  2011-12-03       Impact factor: 5.038

3.  [The future of depression research].

Authors:  F Holsboer
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

4.  Correlation of major depressive disorder symptoms with FKBP5 but not FKBP4 expression in human immunodeficiency virus-infected individuals.

Authors:  Erick T Tatro; Timothy B Nguyen; Chad A Bousman; Eliezer Masliah; Igor Grant; J Hampton Atkinson; Ian P Everall
Journal:  J Neurovirol       Date:  2010-10       Impact factor: 2.643

5.  Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity.

Authors:  Jing Liu; Ming Guo; Di Zhang; Shao-Ying Cheng; Meilian Liu; Jun Ding; Philipp E Scherer; Feng Liu; Xin-Yun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

6.  Glucocorticoid receptor deletion from the dorsal raphé nucleus of mice reduces dysphoria-like behavior and impairs hypothalamic-pituitary-adrenocortical axis feedback inhibition.

Authors:  Melanie Y Vincent; Lauren Jacobson
Journal:  Eur J Neurosci       Date:  2014-03-29       Impact factor: 3.386

7.  Temporal patterns, heterogeneity, and stability of diurnal cortisol rhythms in children with autism spectrum disorder.

Authors:  Andrew J Tomarken; Gloria T Han; Blythe A Corbett
Journal:  Psychoneuroendocrinology       Date:  2015-08-21       Impact factor: 4.905

8.  Preliminary evidence that hippocampal volumes in monkeys predict stress levels of adrenocorticotropic hormone.

Authors:  David M Lyons; Karen J Parker; Jamie M Zeitzer; Christine L Buckmaster; Alan F Schatzberg
Journal:  Biol Psychiatry       Date:  2007-06-14       Impact factor: 13.382

Review 9.  Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.

Authors:  Thaddeus W W Pace; Fang Hu; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2006-10-27       Impact factor: 7.217

10.  Regulation of corticosteroid receptor gene expression in depression and antidepressant action.

Authors:  N Barden
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.